A 52 week, multi-center, randomized, double-blind placebocontrolled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2021
This article has no abstract
Epistemonikos ID: 815e1317ca3c1b56457bbb06ff4c40618c5f6a86
First added on: Apr 11, 2025